Eiger Biopharmaceuticals (NASDAQ:EIGR) and Vical (NASDAQ:VICL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
This table compares Eiger Biopharmaceuticals and Vical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Eiger Biopharmaceuticals and Vical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Eiger Biopharmaceuticals currently has a consensus price target of $30.82, indicating a potential upside of 175.15%. Vical has a consensus price target of $4.00, indicating a potential upside of 455.56%. Given Vical’s higher probable upside, analysts clearly believe Vical is more favorable than Eiger Biopharmaceuticals.
Valuation and Earnings
This table compares Eiger Biopharmaceuticals and Vical’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eiger Biopharmaceuticals||N/A||N/A||-$52.39 million||($3.82)||-2.93|
|Vical||$1.62 million||10.15||-$16.25 million||($0.81)||-0.89|
Vical has higher revenue and earnings than Eiger Biopharmaceuticals. Eiger Biopharmaceuticals is trading at a lower price-to-earnings ratio than Vical, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Eiger Biopharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Vical has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.
Insider and Institutional Ownership
80.0% of Eiger Biopharmaceuticals shares are owned by institutional investors. Comparatively, 33.8% of Vical shares are owned by institutional investors. 5.8% of Eiger Biopharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Vical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Vical beats Eiger Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Vical Company Profile
Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.